drugset
drugset / Trial / NCT04274452

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)

NCT04274452 ↗

Phase 3 Withdrawn argenx
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.

Timeline

Start
2020-06-29
Primary completion
2021-09-01
Completion
2021-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Efgartigimod Alfa Protein / enzyme biologic 10 mg/kg Intravenous

Indications

autoimmune thrombocytopenia